Literature DB >> 24081785

Radiologic resectability assessment in pancreatic cancer.

T Denecke1, C Grieser1, P Neuhaus2, M Bahra2.   

Abstract

Complete tumor resection is still the only potentially curative therapy option for patients with ductal adenocarcinoma of the pancreas. Surgical exploration is the gold standard for the determination of tumor resectability. Radiological resectability assessment is of great importance because many clearly unresectable cases can be identified preoperatively and it became essential for surgical planning. The evolving surgical and radiological techniques demand a continuous reappraisal of radiological criteria in resectability assessment. In the following, the criteria for resection planning are described along with surgical management and the role of radiology in some innovative surgical concepts is explained. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 24081785     DOI: 10.1055/s-0033-1350190

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  3 in total

Review 1.  Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival.

Authors:  Marianne Sinn; Marcus Bahra; Timm Denecke; Sue Travis; Uwe Pelzer; Hanno Riess
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

2.  Anterior approach in situ resection for total laparoscopic pancreaticoduodenectomy.

Authors:  Yunqiang Cai; He Cai; Bing Peng
Journal:  BMC Surg       Date:  2021-12-18       Impact factor: 2.102

3.  Mesopancreatic Stromal Clearance Defines Curative Resection of Pancreatic Head Cancer and Can Be Predicted Preoperatively by Radiologic Parameters: A Retrospective Study.

Authors:  Ulrich F Wellner; Tobias Krauss; Agnes Csanadi; Hryhoriy Lapshyn; Louisa Bolm; Sylvia Timme; Birte Kulemann; Jens Hoeppner; Simon Kuesters; Gabriel Seifert; Dirk Bausch; Oliver Schilling; Yogesh K Vashist; Thomas Bruckner; Mathias Langer; Frank Makowiec; Ulrich T Hopt; Martin Werner; Tobias Keck; Peter Bronsert
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.